Additional information
| Trade Name | Imbruvica |
|---|---|
| Generic Name | Ibrutinib |
| Manufacturer | AbbVie |
| Drug Type | Oncology |
| Indication | Blood cancer / Leukamia |
| Doasage Form | Capsules |
| Packaging | 90 Capsules |
IMBRUVICA (Ibrutinib)-140 mg
IMBRUVICA (Ibrutinib) is a targeted therapy, works against cancerous B lymphocytes, a type of white blood cells. It inhibits the function of Bruton’s tyrosine kinase (BTK), an enzyme that promotes the survival of B lymphocytes and their migration to the organs where these cells normally divide.
It is used in the treatment of ;
- Chronic graft-versus-host (cGVHD) disease after failure of one or more prior lines of systemic therapy.
- Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
- Mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
- Waldenstrom’s macroglobulinemia
